Article

'Great news' for people with cancer

Author(s):

In one of its most anticipated rulings in recent memory, the U.S. Supreme Court decided the Patient Protection and Affordable Care Act does not violate the Constitution and can remain the law of the land. (You can read the full ruling here.)The big news for people with cancer? It means that they will not be refused insurance coverage because of a pre-existing condition. It means that young cancer survivors will continue being covered by their parents' insurance until they reach age 26. It means essential cancer screening procedures will be covered. For additional details, check the story we ran in 2010 when the legislation first became law.The response from our friends and followers on social media was immediate and overwhelmingly positive. (You can see all comments here.) Many people, like Kathi, say it is "great news" for cancer patients and their families. Judith says it is "absolute, utter relief." Amy says it's great news for people with pre-existing conditions. Elizabeth echoes her sentiment: "I am so excited! I've always had health insurance, and have become more thankful for it since being diagnosed cancer. As a cancer patient anxiously awaiting to get her first clean scan, knowing that I no longer have to worry about my pre-existing condition. Whew!"So, what do you think?

Related Videos
Dr. Aditya Bardia is a professor in the Department of Medicine, Division of Hematology/Oncology, director of Translational Research Integration, and a member Signal Transduction and Therapeutics, at University of California, Los Angeles (UCLA) Health Jonsson Comprehensive Cancer Center.
Dr. Laura Dawson, a professor and chair of the department of Radiation Oncology at the University of Toronto, and a practicing radiation oncologist in the Radiation Medicine Program at Princess Margaret Cancer Center, University Health Network in Toronto.
Dr. Sattva S. Neelapu, a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr. Michael Bogenschutz, director of the NYU Langone Center for Psychedelic Medicine in New York,
1 expert is featured in this series.
Dr. Richard “Rick" Winneker
Dr Sattva S. Neelapu discusses data from the ZUMA-5 trial investigating the CAR T-cell therapy Yescarta in relapsed/refractory follicular lymphoma
1 expert is featured in this series.
Related Content